Project: Synergistic platform for the identification of small molecule drug leads for cancer immunotherapy
Develop, implement and commercialize an innovative drug discovery platform to identify small molecule compounds that modulate the activity of hallmark proteins in cancer that are difficult to drug. To obtain proof-of-principle, two key enzymes involved in the regulation of the body’s immune response against cancer cells will be screened by DNA-encoded small molecule compound libraries. Hits will subsequently be optimised to leads or pre-clinical candidates and out-licensed to pharma companies.
| Acronym | ImmunoTherapyScreen (Reference Number: 9617) |
| Duration | 01/07/2015 - 01/07/2017 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 3 |